SecBot SecBot
Institutional Cluster

JANX

Janux Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed4mo ago
Institutional cluster: 4 buyers, 3 sellers (mixed)
Actionable Insight • Neutral

The cluster lacks conviction signal as it is dominated by passive rebalancing. Monitor for upcoming catalysts (clinical data, earnings) rather than reading this as directional. Citadel's trim may indicate near-term caution despite passive accumulation.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
JANX ▲ +48.17% at T+60d
NEUTRAL call +48.17% · α vs SPY +43.77% · entry $13.66 → $20.24
Entry = T+0 close
Jun 11, 2026
via day close
T+1d
-0.73%
call -0.73% · α -1.27%
$13.56
settled 5mo ago
T+5d
+3.59%
call +3.59% · α +3.15%
$14.15
settled 4mo ago
T+20d
+22.62%
call +22.62% · α +20.73%
$16.75
settled 4mo ago
T+60d
+48.17%
call +48.17% · α +43.77%
$20.24
settled 7w ago

Executive Summary

Institutional cluster for JANX shows mixed Q3 activity: four passive buyers (State Street, Invesco, UBS, Morgan Stanley) added $21.9M while three sellers (T. Rowe Price, Citadel, BofA) reduced by $16.6M, net buying ~$5.3M. The cluster is dominated by passive/index rebalancing with no clear active conviction, and Citadel's trim adds a note of caution.

Key Financial Metrics

Direction
mixed
Buy Value
$68.5M
Net Flow
$5.3M

Institutional Positions

Net institutional flow: $5.3M

▲ Buyers (4)

InstitutionActionChangePosition ValueValue Δ
State StreetADD+36.3%$46.2M$14.2M
Morgan StanleyADD+57%$12.1M$4.8M
UBSADD+33.4%$9.5M$2.8M
InvescoADD+33.7%$598.0K$175.0K

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
CitadelTRIM-34.8%$28.4M-$8.8M
BofATRIM-42.6%$19.9M-$7.8M

Key Facts

  • 4 institutional buyers added $21.9M in Q3, all mega-passive managers (State Street, Invesco, UBS, Morgan Stanley)
  • 3 institutional sellers reduced $16.6M, including quant fund Citadel trimming -34.8% and passive (BofA, T. Rowe Price)
  • Net institutional flow positive ~$5.3M but signal weak due to passive dominance and mixed direction

Financial Impact

Net institutional buying of approximately $5.3M, representing ~0.66% of $802M market cap

institutional ownershipposition concentration

Risk Factors

  • Passive-dominated flows may reverse next quarter with index rebalancing
  • Quant selling (Citadel) could precede further distribution
  • Poor historical cluster performance on JANX suggests limited predictive value

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-JANX-2025-Q3
4 reports for JANX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for JANX — sortable, filterable
TypeNow
Jun 23, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$14.64 $16.86▲ +15.16%▲ +12.33%—
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 2/10
$13.66 $20.24▲ +48.17%▲ +43.77%—
May 7, 2026
24w ago
8-K
NEUTRAL ★ 4/10
$14.18 $15.96▲ +12.59%▲ +7.75%—
Feb 28, 2026
34w ago
Institutional Cluster
BULLISH ★ 7/10
$13.42 $14.40▲ +7.30%▼ −2.02%—
Showing 4 of 4

US Market Status

Market Open — Closes in 3h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026